NAVB Statistics
Total Valuation
Navidea Biopharmaceuticals has a market cap or net worth of 9,999. The enterprise value is -2.30 million.
| Market Cap | 9,999 |
| Enterprise Value | -2.30M |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Navidea Biopharmaceuticals has 99.99 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 99.99M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +105.97% |
| Owned by Insiders (%) | 35.92% |
| Owned by Institutions (%) | 0.00% |
| Float | 64.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.09 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1.66 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.24 |
Financial Position
The company has a current ratio of 0.56
| Current Ratio | 0.56 |
| Quick Ratio | 0.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -107.05% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 47 |
| Profits Per Employee | -106,882 |
| Employee Count | 13 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.15 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.82% in the last 52 weeks. The beta is 1.46, so Navidea Biopharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | -99.82% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 28.21 |
| Average Volume (20 Days) | 30,833 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Navidea Biopharmaceuticals had revenue of 610 and -1.39 million in losses. Loss per share was -0.03.
| Revenue | 610 |
| Gross Profit | -49,426 |
| Operating Income | -10.24M |
| Pretax Income | -8.61M |
| Net Income | -1.39M |
| EBITDA | -10.13M |
| EBIT | -10.24M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 3.86 million in cash and 1.26 million in debt, giving a net cash position of 2.61 million or 0.03 per share.
| Cash & Cash Equivalents | 3.86M |
| Total Debt | 1.26M |
| Net Cash | 2.61M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | -2.98M |
| Book Value Per Share | -0.03 |
| Working Capital | -3.48M |
Cash Flow
In the last 12 months, operating cash flow was -9.71 million and capital expenditures -15,068, giving a free cash flow of -9.73 million.
| Operating Cash Flow | -9.71M |
| Capital Expenditures | -15,068 |
| Free Cash Flow | -9.73M |
| FCF Per Share | -0.10 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,678,790.98% |
| Pretax Margin | -1,411,062.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Navidea Biopharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -75.79% |
| Shareholder Yield | -75.79% |
| Earnings Yield | -26,045.00% |
| FCF Yield | -97,293.63% |
Stock Splits
The last stock split was on April 26, 2019. It was a reverse split with a ratio of 0.05.
| Last Split Date | Apr 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
Navidea Biopharmaceuticals has an Altman Z-Score of -100.92. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -100.92 |
| Piotroski F-Score | n/a |